Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

Abstract

In the above-mentioned article, the spelling of 5 authors last names has been wrong and these names have been corrected.This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports

“…As far as we know, there are no documented cases where NMS raised clozapine serum levels. Any inflammatory state that raises CRP may affect clozapine metabolism (Leon et al, 2022), but in Patient 2 CRP was low and he had no marked temperature elevation, thus making infection or inflammation an unlikely reason for such a significant elevation of clozapine serum levels.…”

“…Co-medicating with disulfiram in clozapine patients is common in clinical settings, but reports on their potential pharmacological interactions are scanty (Brenner et al, 1994). Caffeine is a known inhibitor of clozapine metabolism through their shared cytochrome P450 CYP1A2 pathway, and drinking large amounts of coffee or other caffeinated drinks may cause clinically relevant increase in clozapine serum levels (Leon et al, 2022; Raaska et al, 2004; Yartsev and Peisah, 2021). Some medications increase clozapine serum levels through inhibition of CYP1A2 pathway, including fluvoxamine (Koponen et al, 1996) and ciprofloxacin (Brouwers et al, 2009).…”

Response to the letter to the Editor from Araujo and colleagues on the research article entitled, “Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment‐resistant schizophrenia receiving clozapine: A 1‐year retrospective cohort study”

“…We did not collect Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), or World Health Organization Disability Assessment Schedule (WHO-DAS) data in our routine clinical practice, nor did we have information on previous treatments or detailed reasons for the use of VPA. As pointed out, the duration of psychiatric hospitalization in Japan is longer than those in other Organization for Economic Cooperation and Development (OECD) countries, 3 and Asians have lower cytochrome P450 (CYP) 1A2 activity and require lower clozapine doses to reach the therapeutic range than those of Caucasians, 4 potentially limiting the generalizability of the results.…”